← Eichor
Study identifier: NCT06248580 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Find HDV and Determine Its Status in Turkey

Condition: Chronic Hepatitis D Infection · Fibrosis, Liver · Hepatocellular Carcinoma  ·  Sponsor: Yaşar Bayındır, MD

PhaseN/A
Planned participants20000
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersYes

About this study

The aim of these study to determine the prevalence of hepatitis Delta virus (HDV) infections and the prognosis of HDV patients in Turkey's southeast. The investigators intend to arrange training sessions for 250 family physicians in Diyarbakir, Batman, Mardin, and Sanliurfa in order to determine those goals. The investigators will talk about diagnosing hepatitis B virus (HBV), HDV, hepatitis C virus (HCV), and Human Immunodeficiency virus (HIV) infections during these events. To ensure that patients with simultaneous HDV infection are evaluated for HIV/HCV and to detect liver fibrosis with a non-invasive method.

This description comes directly from the study's public registry record.

Talk to the study team

Yaşar Bayındır, MD  ·  00905323659909  ·  yasar.bayindir@guven.com.tr

Mustafa Kemal Çelen, MD  ·  00905336207022

Always discuss trial participation with your own doctor first.

Locations (2)

Guven HospitalAnkara, Turkey (Türkiye)Recruiting
Dicle University, Faculty of MedicineDiyarbakır, Turkey (Türkiye)Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06248580